Monday, 10 February 2014

Number of people diagnosed with diabetes reaches 3.2 million

The new figures, extracted from official NHS data, show that there were 3,208,014 adults with the condition in 2013, an increase of more than 163,000 compared to 2012 (Diabetes UK)


Merck and Samsung Bioepis Enter Collaboration Agreement to Develop and Commercialize Insulin Glargine Candidate for Diabetes

MSD and Samsung Bioepis announce that they have expanded their collaboration with an agreement to develop, manufacture and commercialize MK-1293, an insulin glargine candidate for the treatment of patients with type 1 and type 2 diabetes. Phase III clinical studies in type 1 and type 2 diabetes will begin soon (Merck)


A comparison of biphasic insulin aspart and insulin glargine administered with oral antidiabetic drugs in type 2 diabetes mellitus

BIAsp 30 added to OAD therapy results in a better glycaemic control as compared with IGlar in T2DM patients. BIAsp 30 use is associated with slightly larger weight gain but no rise in risk of severe hypoglycaemic episodes (International Journal of Clinical Practice)


High plasma estradiol interacts with diabetes on risk of dementia in older postmenopausal women

High E2 level is an independent predictor of incident dementia, particularly in postmenopausal women with diabetes (Neurology)


GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?

GLP-1RAs provide superior glycaemic control and weight loss vs. DPP-4 inhibitors in patients with T2D. DPP-4 inhibitors may sometimes be preferred to a GLP-1RA if weight is not a concern, oral administration is a desirable feature or when a GLP-1RA cannot be tolerated (International Journal of Clinical Practice)

No comments:

Post a Comment